NewAmsterdam Pharma Co N.V. (NAMS) Stock
Company insiders reported 1 open-market buy and 3 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Are NewAmsterdam Pharma Co N.V. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 30, 26 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | SELL | 50.2K | $1.3M |
| Sep 14, 26 | Davidson Michael H. | Chief Executive Officer | BUY | 10.0K | $227K |
| Sep 4, 26 | Smither John W | Director | SELL | 1.6K | $41K |
| Aug 24, 26 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | SELL | 125.0K | $3.4M |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →NAMS price chart
Powered by TradingViewWhat does NewAmsterdam Pharma Co N.V. do?
NewAmsterdam Pharma Co. N.V. is a pharmaceutical company focused on the research, development, and commercialization of transformative therapies addressing cardiovascular diseases. The company's primary mission is to innovate in the cardiovascular space by introducing medications that meet the evolving needs of patients worldwide. Notably, NewAmsterdam Pharma is at the forefront of developing novel treatments aimed at reducing cardiovascular risk and improving patient outcomes. Operating within the life sciences sector, the company leverages advanced scientific research and development capabilities to push forward its pipeline of projects. By concentrating specifically on cardiovascular therapies, NewAmsterdam Pharma aims to significantly impact a critical area of healthcare that affects millions globally. In the financial markets, the company represents an essential player within the pharmaceutical industry, focused on addressing unmet medical needs. Its work has substantial implications for both the healthcare sector and broader economic landscapes, illustrating the importance of continuous innovation in tackling global health challenges.